Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 9;31(163):210208.
doi: 10.1183/16000617.0208-2021. Print 2022 Mar 31.

Clinical significance and applications of oscillometry

David A Kaminsky  1   2 , Shannon J Simpson  3   2 , Kenneth I Berger  4 , Peter Calverley  5 , Pedro L de Melo  6 , Ronald Dandurand  7   8 , Raffaele L Dellacà  9 , Claude S Farah  10 , Ramon Farré  11   12 , Graham L Hall  3 , Iulia Ioan  13   14 , Charles G Irvin  1 , David W Kaczka  15 , Gregory G King  16   17 , Hajime Kurosawa  18 , Enrico Lombardi  19 , Geoffrey N Maksym  20 , François Marchal  13   14 , Ellie Oostveen  21 , Beno W Oppenheimer  4 , Paul D Robinson  22 , Maarten van den Berge  23 , Cindy Thamrin  17
Affiliations
Review

Clinical significance and applications of oscillometry

David A Kaminsky et al. Eur Respir Rev. .

Abstract

Recently, "Technical standards for respiratory oscillometry" was published, which reviewed the physiological basis of oscillometric measures and detailed the technical factors related to equipment and test performance, quality assurance and reporting of results. Here we present a review of the clinical significance and applications of oscillometry. We briefly review the physiological principles of oscillometry and the basics of oscillometry interpretation, and then describe what is currently known about oscillometry in its role as a sensitive measure of airway resistance, bronchodilator responsiveness and bronchial challenge testing, and response to medical therapy, particularly in asthma and COPD. The technique may have unique advantages in situations where spirometry and other lung function tests are not suitable, such as in infants, neuromuscular disease, sleep apnoea and critical care. Other potential applications include detection of bronchiolitis obliterans, vocal cord dysfunction and the effects of environmental exposures. However, despite great promise as a useful clinical tool, we identify a number of areas in which more evidence of clinical utility is needed before oscillometry becomes routinely used for diagnosing or monitoring respiratory disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D.A. Kaminsky reports personal payments made as faculty speaker for Cardiorespiratory Diagnostics Seminar from MGC Diagnostics, Inc. outside the submitted work. Past Chair of ATS Proficiency Standards for Pulmonary Function Laboratories Committee, unpaid. Conflict of interest: S.J. Simpson has nothing to disclose. Conflict of interest: K.I. Berger has nothing to disclose. Conflict of interest: P. Calverley reports receiving consulting fees paid by Phillips Respironics for advisory work on a novel COPD ventilator. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Phillips Respironics, outside the submitted work. Conflict of interest: P.L. de Melo reports patent 28727 issued. Conflict of interest: R.J. Dandurand reports grants or contracts paid to the institution from AstraZeneca, Boehringer-Ingelheim, Covis Pharma, Grifols, MGC Diagnostics, Teva Pharma, Thorasys, and Vyaire, outside the submitted work. Speaking payment from Novartis for L'oscillométrie en clinique: qu'ajoute-t-elle aux évaluations pulmonaires?, 18 September 2019, Boehringer-Ingelheim for L'oscillométrie: vieille physiologie avec un avenir brilliant, 17 November 2020, and Latin American Respiratory Physiology Society for Oscillometry in Asthma and COPD: Interpretation Strategies, 14 November 2020, outside the submitted work. Chairman, Oscillometry Harmonisation Study Group, an international committee academic and industry experts working to standardise oscillometry devices, and Chairman, Respiratory Effectiveness Group Technologies Working Group, Cambridge, U.K. (https://www.regresearchnetwork.org). Conflict of interest: R.L. Dellacà reports royalties or licenses from Restech, Philips and Vyaire. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Restech and Philips, outside the submitted work. Support for attending meetings from Philips and Vyaire. Patent issued, owned and licensed from Politecnico di Milano University. Member of the Board of Directors for Restech. Stocks owned for Restech. Free loan of equipment for studies received from Vyaire and Restech. Conflict of interest: C.S. Farah has nothing to disclose. Conflict of interest: R. Farré has nothing to disclose. Conflict of interest: G.L. Hall has nothing to disclose. Conflict of interest: I. Ioan has nothing to disclose. Conflict of interest: C.G. Irvin received consulting fees from Medical Graphics Corporation, outside the submitted work. Conflict of interest: D.W. Kaczka reports support for the present manuscript from University of Iowa. Grants or contracts from Dept of Defence and NIH, outside the submitted work. Consulting fees received from ZOLL Medical, Inc. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from CHEST, ASME, Medical Society of New Zealand, and Johns Hopkins University, outside the submitted work. US patent 10,675,423 B2 (patent on MFOV technique, inventor) and PCT patent pending, patent on MFOV technique pending. Stock or stock options held for OscillaVent, Inc. Loan of ventilator for other projects from ZOLL Medical Inc. Conflict of interest: G.G. King reports grants or contracts from Restech Italy, NHMRC, Boehringer Ingelheim, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma, Philanthropic individuals and societies, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CycloPharm, GlaxoSmithKline, Menarini, MundiPharma and Novartis, outside the submitted work. Leadership or fiduciary role in other board, society, committee or advocacy group for ERS Technical Standards for Respiratory Oscillometry. Conflict of interest: H. Kurosawa reports receiving a grant from CHEST Co. Ltd. Royalties or licence for CHEST Co. Ltd. Payment or honoraria for lectures received from CHEST Co. Ltd. Nippon, Boehringer Ingelheim, Novartis, and Teijin Pharma, outside the submitted work. Conflict of interest: E. Lombardi reports grants or contracts from Restech and Sanofi, outside the submitted work. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events received from Angelini, Chiesi, GSK, Novartis and Sanofi, outside the submitted work. Participation on a Data Safety Monitoring Board or Advisory Board for GSK and Novartis. Conflict of interest: G.N. Maksym reports grants or contracts from National Research Council of Canada, Cyclomedica Inc. Australia, and Lung Association of Nova Scotia, outside the submitted work. Accommodation Expenses received from Thorasys, Thoracic Medical Systems Inc. for attending European Society Meeting 2019. Patents planned, issued or pending for Method and system to acquire oscillometry measurements, owned by Thorasys, Thoracic Medical Systems Inc. Stock or stock options held for Thorasys, Thoracic Medical Systems Inc. Conflict of interest: F. Marchal has nothing to disclose. Conflict of interest: E. Oostveen has nothing to disclose. Conflict of interest: B.W. Oppenheimer has nothing to disclose. Conflict of interest: P.D. Robinson has nothing to disclose. Conflict of interest: M. van den Berge reports grants or contracts from GlaxoSmithKline, Novartis, Astra Zeneca, Roche, and Genentech, outside the submitted work. Conflict of interest: C. Thamrin report grants or contracts from Restech SRL and THORASYS Thoracic. Equipment on loan for research studies from Restech SRL and THORASYS Thoracic, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Impedance spectrum. Respiratory system impedance (Zrs) is plotted against frequency. Zrs is composed of a real component seen by resistance (Rrs) and an imaginary component expressed as reactance (Xrs). Rrs and Xrs at specific frequencies are noted by the frequency at which they are measured (e.g. Rrs5=Rrs at 5 Hz, Rrs20=Rrs at 20 Hz). The point at which Xrs crosses zero is the resonant frequency (fres). Below fres, Xrs is dominated by elastance, and above fres, Xrs is dominated by inertance. An integrated measure of low frequency Xrs is the area inscribed by Xrs and Zrs=0 starting at the lowest frequency up to fres, known as the area of the Xrs curve, AX. The lowest frequency defining AX is shown at 5 Hz, but it may be estimated starting from any frequency. Note that the Zrs spectrum shown is characteristic for a healthy adult. In healthy young children, the values and frequency dependence of Rrs would be relatively increased, Xrs would be more negative and fres would be shifted markedly to the right (resulting in increased AX).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Calverley PMA, Farré R. Oscillometry: old physiology with a bright future. Eur Respir J 2020; 56: 2001815. doi:10.1183/13993003.01815-2020 - DOI - PubMed
    1. King GG, Bates J, Berger KI, et al. . Technical standards for respiratory oscillometry. Eur Respir J 2020; 55: 1900753. doi:10.1183/13993003.00753-2019 - DOI - PubMed
    1. Dandurand RJ, Lavoie JP, Lands LC, et al. . Comparison of oscillometry devices using active mechanical test loads. ERJ Open Res 2019; 5: 00160-2019. doi:10.1183/23120541.00160-2019 - DOI - PMC - PubMed
    1. Oostveen E, Boda K, van der Grinten CP, et al. . Respiratory impedance in healthy subjects: baseline values and bronchodilator response. Eur Respir J 2013; 42: 1513–1523. doi:10.1183/09031936.00126212 - DOI - PubMed
    1. Hall GL, Hantos Z, Wildhaber JH, et al. . Contribution of nasal pathways to low frequency respiratory impedance in infants. Thorax 2002; 57: 396–399. doi:10.1136/thorax.57.5.396 - DOI - PMC - PubMed